L
Liliana H. Mochmann
Researcher at Charité
Publications - 14
Citations - 534
Liliana H. Mochmann is an academic researcher from Charité. The author has contributed to research in topics: Leukemia & Acute leukemia. The author has an hindex of 9, co-authored 11 publications receiving 446 citations. Previous affiliations of Liliana H. Mochmann include German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
TL;DR: In this paper, the authors summarized key findings leading to aberrant activation of PI3K/AKT/mTOR pathways in acute leukemia and reflected on both promises and challenges of targeting PI3k/AKt/mtor in the acute leukemia setting.
Journal ArticleDOI
FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors.
Martin Neumann,Ebru Coskun,Lars Fransecky,Liliana H. Mochmann,Isabelle Bartram,Nasrin Farhadi Sartangi,Sandra Heesch,Nicola Gökbuget,Stefan Schwartz,Christian Brandts,Cornelia Schlee,Rainer Haas,Ulrich Dührsen,Martin Griesshammer,Hartmut Döhner,Gerhard Ehninger,Thomas Burmeister,Olga Blau,Eckhard Thiel,Dieter Hoelzer,Wolf-Karsten Hofmann,Claudia D. Baldus +21 more
TL;DR: FLT3 mutated ETP-ALL defines a molecular distinct stem cell like leukemic subtype and warrants clinical studies with the implementation of FLT3 inhibitors in addition to early allogeneic stem cell transplantation for this high risk subgroup.
Journal ArticleDOI
Molecular alterations in bone marrow mesenchymal stromal cells derived from acute myeloid leukemia patients
E K von der Heide,E K von der Heide,Martin Neumann,Martin Neumann,Sebastian Vosberg,Sebastian Vosberg,Alva Rani James,Alva Rani James,Michael P Schroeder,Michael P Schroeder,Jutta Ortiz-Tanchez,Jutta Ortiz-Tanchez,Konstandina Isaakidis,Konstandina Isaakidis,Cornelia Schlee,Cornelia Schlee,M Luther,M Luther,Korinna Jöhrens,Ioannis Anagnostopoulos,Liliana H. Mochmann,Liliana H. Mochmann,Daniel Nowak,Wolf-Karsten Hofmann,Philipp A. Greif,Philipp A. Greif,Claudia D. Baldus,Claudia D. Baldus +27 more
TL;DR: Molecular alterations in AML BM-MSC are reported suggesting global changes in the AMLBM microenvironment, and extended investigations of these altered niche components may contribute to the design of niche-directed therapies inAML.
Journal ArticleDOI
Antileukemic activity of the HSP70 inhibitor pifithrin-μ in acute leukemia.
Martin Kaiser,Andrea Kühnl,Jana Reins,Fischer S,Jutta Ortiz-Tanchez,Cornelia Schlee,Liliana H. Mochmann,Sandra Heesch,Ouidad Benlasfer,Wolf-Karsten Hofmann,Eckhard Thiel,Claudia D. Baldus +11 more
TL;DR: This is the first study demonstrating significant antileukemic effects of the HSP70 inhibitor P FT-μ, alone and in combination with different antineoplastic drugs in both AML and ALL, and suggests a potential therapeutic role for PFT-μ in acute leukemias.
Journal ArticleDOI
Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia.
Andrea Kühnl,Nicola Gökbuget,Martin Kaiser,Cornelia Schlee,Andrea Stroux,Thomas Burmeister,Liliana H. Mochmann,Dieter Hoelzer,Wolf-Karsten Hofmann,Eckhard Thiel,Claudia D. Baldus +10 more
TL;DR: High LEF1 expression identifies B-precursor ALL patients with inferior RFS, supporting a pathogenetic role of Wnt signaling in ALL and standard-risk patients with high LEf1 expression might benefit from early treatment modifications and new molecular therapies, including agents targeting the Wnt pathway.